Two companies are getting closer to public statute, today's edition of the State Gazette reveals. These are Unipharm and Darvoobrabotvane BT.

Unipharm AD has appointed a general meeting of shareholders in order to change the type of its shares, to adopt a decision for the company's bourse listing, as well as to make amendments to the statute.

Unipharm's core activity includes the production of medicines, scientific experimental work on new technologies for medicine production in Bulgaria and others.

In H2 last year the company increased capital from 200,000 leva (102,258 euros) to 500,000 leva (255,645 euros).

The State Gazette also announces today that Darvoobrabotvane BT is to increase capital from 828,000 leva (423,349 euros) to 3.4 mln leva (1.738 mln euros) using company reserves.

Darvoobrabotvane BT posted net profit in the amount of 351,000 leva (179,463 euros) in 2006, and 617,000 leva (316,467 euros) in 2005.

The company expects to generate some 13 mln leva (6.646 mln euros) in revenues in 2007, 18.47 mln leva (9.443 mln euros) in 2008, and 21.85 mln leva (11.171 mln euros) in 2009. Net profit this year is projected at 1.565 mln leva (800,171 euros), 2.451 mln leva (1.253 mln euros) in 2008, and 3.161 mln leva (1.616 mln euros) in 2009, according to company's prognoses.

Yesterday Darvoobrabotvane's Atanas Vasilev told profit.bg in an interview that the company is planning another BSE listing, and will use the funds raised through it to finance one of its new projects.